This ad will close in 15 seconds

From : 7260678
Added: Nov 12, 2009
~~Cabergoline~~不影響胚胎著床!!! 可治過度刺激!!! 1.2.3.4.8.9.6.10.7 Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model Raul Gomez, Miguel Gonzalez-Izquierdo, Ralf C. Zimmermann, Edurne Novella-Maestre, Isabel Alonso-Muriel,Jose Sanchez-Criado, Jose Remohi, Carlos Simon and Antonio Pellicer Department of Obstetrics and Gynecology (R.G., R.C.Z.), Columbia University, New York, New York 10032; University Institute (R.G., E.N.-M., I.A.-M., J.R., C.S., A.P.), Instituto Valenciano de Infertilidad (J.R., C.S., A.P.), University of Valencia, 46015 Valencia, Spain; Hospital Dr Peset (M.G.-I., A.P.), 46017 Valencia, Spain; and Department of Cell Biology, Physiology, and Immunology (J.S.-C.), University of Cordoba, 14004 Cordoba, Spain Address all correspondence and requests for reprints to: Raul Gomez, Department of Obstetrics and Gynecology, Columbia University, 630 West 168th Street, P&S Building 16-438, New York, New York 10032. E-mail: rg2278@columbia.edu. No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertilewomen treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion ofvascular endothelial growth factor (VEGF)-activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist (SU5416). However, due to its toxicity (thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, used in the treatment of human hyperprolactinemia including pregnancy, inhibit VEGFR-2-dependent VP and angiogenesis when administered at high doses in animal cancer models. To test whether VEGFR-2-dependent VP and angiogenesis could be segregated in a dose-dependent fashion with the Dp-r2 agonist cabergoline, a well-established OHSS rat model supplemented with prolactin was used. A 100 µg/kg low-dose Dp-r2 agonist cabergoline reversed VEGFR-2-dependent VP without affecting luteal angiogenesis through partial inhibition of ovarian VEGFR-2 phosphorylation levels. No luteolytic effects (serum progesterone levels and luteal apoptosis unaffected) were observed. Cabergoline administration also did not affect VEGF/VEGFR-2 ovarian mRNA levels. Results in the animal model and the safe clinical profile of Dp-r2 agonists encouraged us to administer cabergoline to oocyte donors at high risk for developing the syndrome. Prophylactic administration of cabergoline (510 µg/kg·d) decreased the occurrence of OHSS from 65% (controls) to 25% (treatment). Therefore, a specific, safe treatment for OHSS is now available.
Category : People

Video Categories:

Also Try: